Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 2587 of 6351
-
Lung cancer patients gain early access to promising new drug
Disease control Expanded access (paused)This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the po…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for chronic dry eye from Graft-Versus-Host disease: expanded access to d-MAPPS eye drops
Disease control Expanded accessRegenerative Ocular Immunobiologics, LLC Fast Track Expanded Access This Expanded Access Policy describes the conditions under which ROI may make its investigational product - Sterile Processed Derived Multiple Allogeneic Proteins Paracrine Signaling (d-MAPPS™ Ophthalmic Solution…
Sponsor: Regenerative Ocular Immunobiologics LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Last-Resort drug access for leukemia patients
Disease control Expanded access (ended)This expanded access program will provide an investigational treatment option in a controlled clinical setting for participants who are not otherwise eligible to participate in other Syndax-sponsored clinical studies and have no approved treatment options.
Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
New drug brensocatib offered to bronchiectasis patients who completed key trial
Disease control ApprovedThe purpose of this study is to allow early access to brensocatib for participants with non-cystic fibrosis bronchiectasis (NCFBE) who have successfully completed the INS1007301 ASPEN Clinical trial.
Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Second chance: nonconforming CAR-T therapy offered to lymphoma patients
Disease control Expanded accessThis is an expanded access protocol that will be conducted at sites qualified and approved to treat subjects with lisocabtagene maraleucel. Sometimes when lisocabtagene maraleucel is manufactured the drug does not pass all the testing results to be called lisocabtagene maraleucel…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for sickle cell patients: expanded access to crizanlizumab
Disease control Expanded accessThe purpose of this registration is to list Managed Access Programs (MAPs) related to SEG101, Crizanlizumab
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for SCA patients: expanded access to investigational drug troriluzole
Disease control Expanded accessThe purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).
Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Last-Resort cancer drug made available to patients with no alternatives
Disease control Expanded access (ended)The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. This expanded access program provides adults with refractory metastatic colorectal cancer (mCRC) and who cannot neither adequately be treated by current standard of care …
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for sarcopenic obesity: expanded access program opens
Disease control Expanded access (paused)The expanded access is designed for patients requesting the treatment, and whose medical condition may benefit from treatment, but are unable to participate in any other IMM01-STEM clinical trial in their physician's opinion for reasons that include: (1) They do not meet enrollme…
Sponsor: Immunis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Early access program offers investigational meningioma treatment
Disease control Expanded accessThis Expanded Access Program (EAP) is intended to provide eligible participants with access to ITM-11 prior to approval by local regulatory authorities. Program availability is subject to country eligibility. The treating physician must determine, based on the individual patient´…
Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Unapproved device trial aims to tame disease
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Lifeline for hunter syndrome patients: continued access to Brain-Targeting therapy
Disease control Expanded accessAs the HGT-HIT-046 (NCT01506141) and SHP609-302 (NCT02412787) studies are completed and closed, this post-trial access (PTA) program provides TAK-609 to participants in these studies for whom the benefit:risk ratio of continued treatment with idursulfase-IT remains positive.
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental device aims to tame disease
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental device aims to tame disease
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Experimental device aims to tame disease without drugs
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Experimental device aims to tame disease
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Can an experimental device ease symptoms? a trial seeks answers
Symptom relief Details not publishedSponsor: [Redacted] • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Can an Oxygen-Boosting drug help when all else fails?
Disease control Expanded accessNanO₂ is an investigational drug being studied by NuvOx Therapeutics. It has not been approved by the U.S. Food and Drug Administration (FDA) for any use. This record describes a way for a patient's own doctor to request NanO₂ for that patient outside of a clinical trial, through…
Sponsor: NuvOx LLC • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could an unapproved device change medical care?
Knowledge-focused Details not publishedSponsor: [Redacted] • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can an experimental device change disease management?
Disease control Details not publishedSponsor: [Redacted] • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC